MedDataX Logo

Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques

NCT ID: NCT05088161

Last Updated: 2021-10-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-13

Study Completion Date

2022-03-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, we will use high-throughput proteomics techniques to search for biomarkers of post-operative prognosis of pancreatic cancer in samples of patients who have been diagnosed with pancreatic cancer through bioinformatics analysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study plan from the affiliated hospital of Qingdao university collected 20 cases of patients with pancreatic cancer pathological tissue samples and clinical data, including clinical diagnostic information, laboratory tests, imaging examination results and other information data), through high-throughput proteomic technology in pancreatic cancer pathological finding biomarkers, the bioinformatics analysis to explore the prognosis biomarkers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of Chinese nationality, age and gender are not limited.
* Pathologically confirmed pancreatic cancer patients.
* Pathological specimens were archived tumor tissue samples after a diagnosis of pancreatic cancer.
* Clinical diagnostic information was complete three months before sampling.

Exclusion Criteria

* Patients with a second primary tumor.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Affiliated Hospital of Qingdao University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yu Cao, Doctor

Role: PRINCIPAL_INVESTIGATOR

the study director of phase I clinical research center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Phase I Clinical Research Center

Qingdao, Shandong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yu Cao, Doctor

Role: CONTACT

[email protected]
86-18661809090

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yu Cao, Doctor

Role: primary

[email protected]
86-18661809090

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JJDB-SR-2021-02

Identifier Type: -

Identifier Source: org_study_id